GU Cancers 2023 | ADCs in the treatment landscape of patients with advanced UC

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses antibody-drug conjugates (ADCs) in the treatment landscape of urothelial carcinoma (UC). Enfortumab vedotin is FDA approved for patients who had progressed on chemotherapy and immunotherapy, including in patients with bone metastases. Data also suggests a benefit of enfortumab vedotin in combination with pembrolizumab with improved response rate and a durability in response that has not yet been achieved with ADCs alone, and is therefore under investigation in the first-line setting. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.